Strong ties have developed between cancer researchers at Meharry Medical College (MMC), Tennessee State University (TSU) and Vanderbilt-lngram Cancer Center (VICC) resulting in this formal Cancer Partnership. Our Partnership is dedicated to enhancing the strengths and eliminating the weaknesses of our three institutions as we move toward our shared goal of eliminating cancer disparities in the US. The U54 award is the bedrock of this collaboration and has moved our collaborative research more forcefully toward a relationship that is based on reciprocity and stronger mutual benefit. The overall objectives of this competing renewal application are: (1) to increase and stabilize the competitive cancer research capability of MMC and TSU;(2) to create stable, long-term collaborative relationships between MMC, TSU and the VICC in cancer research, research training, career development and cancer outreach;and (3) to improve the effectiveness of VICC research, training, career development, cancer education and cancer outreach activities specifically designed to benefit minority populations in the region served by VICC. Funds provided by this U54 will solidify our collaboration. During this phase of our Cancer Partnership, we continue to concentrate on amassing sufficient infrastructure for cancer research that will strengthen reciprocity between MMC, TSU and VICC. In addition to funding two full projects and two pilot studies involving collaborators from all three institutions, funds will be used to recruit investigators to TSU and VICC and to strengthen infrastructure in basic, epidemiologic and clinical cancer research through the support of core facilities providing expertise in biostatistics, clinical trial accruals, histopathology and cancer outreach. All activities involve coordinated, well-planned interactions between MMC, TSU and VICC and will be monitored by an Internal Advisory Committee composed of members from each institution and a Program Steering Committee composed of external, nationally-recognized cancer investigators and representation from the National Cancer Institute. A sustained and comprehensive Cancer Partnership is of immense benefit to the three participating institutions as well as the mid-South region of the US. The institution's complementary strengths will help the Cancer Partnership establish effective cancer research and increase training opportunities at two minority-serving institutions enhance community- and population-based science research targeting minority cancer-related disparities and increase training of minority scientists at an NCI-funded Comprehensive Cancer Center.

Public Health Relevance

Our Cancer Partnership provides an exceptional environment and focus for the efforts of diverse investigators working across many disciplines to identify the determinants ofthe disproportionate share of the cancer burden borne by African Americans, as evidenced by higher incidence rates and compounded by lower rates of relative survival. The conduct of minority-targeted cancer research, development of research infrastructure, enhancement of minority training programs and improvement to the capacity/effectiveness of cancer-related activities will help address these health disparities at the partnering institutions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA163066-03
Application #
8539353
Study Section
Special Emphasis Panel (ZCA1-SRLB-Y (O1))
Program Officer
Wali, Anil
Project Start
2011-09-23
Project End
2016-08-31
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
3
Fiscal Year
2013
Total Cost
$688,440
Indirect Cost
$186,620
Name
Tennessee State University
Department
Social Sciences
Type
Schools of Arts and Sciences
DUNS #
108814179
City
Nashville
State
TN
Country
United States
Zip Code
37209
Yasmin, Sharia; Whalen, Margaret (2018) Flame retardants, hexabromocyclododecane (HCBD) and tetrabromobisphenol a (TBBPA), alter secretion of tumor necrosis factor alpha (TNF?) from human immune cells. Arch Toxicol 92:1483-1494
Brown, Shyretha; Wilburn, Wendy; Martin, Tyesha et al. (2018) Butyltin compounds alter secretion of interleukin 6 from human immune cells. J Appl Toxicol 38:201-218
Vercruysse, Koen; Clark, Astiney; Alatas, Noor et al. (2018) Polysaccharide-mediated synthesis of melanins from serotonin and other 5-hydroxy indoles. Future Sci OA 4:FSO280
Husaini, Baqar A; Taira, Deborah; Norris, Keith et al. (2018) Depression Effects on Hospital Cost of Heart Failure Patients in California: An Analysis by Ethnicity and Gender. Indian J Community Med 43:49-52
Lawrence, Shanieek; Ismail, Farah; Jamal, Sarah Z et al. (2018) Tributyltin stimulates synthesis of interferon gamma and tumor necrosis factor alpha in human lymphocytes. J Appl Toxicol 38:1081-1090
Alotaibi, Dalal; Amara, Suneetha; Johnson, Terrance L et al. (2018) Potential anticancer effect of prostratin through SIK3 inhibition. Oncol Lett 15:3252-3258
Brown, Shyretha; Boules, Mariam; Hamza, Nafisa et al. (2018) Synthesis of interleukin 1 beta and interleukin 6 in human lymphocytes is stimulated by tributyltin. Arch Toxicol 92:2573-2586
Odoh, C; Sanderson, M; Williams, E A et al. (2018) Operationalizing outcome measures of human papillomavirus vaccination among adolescents. Public Health 159:129-132
Husaini, Baqar; Levine, Robert; Lammers, Phillip et al. (2017) Smoking, depression, and hospital costs of respiratory cancers: Examining race and sex variation. Fam Med Community Health 5:29-42
Hull, Pamela; Emerson, Janice S; Quirk, Meghan E et al. (2017) A Smartphone App for Families With Preschool-Aged Children in a Public Nutrition Program: Prototype Development and Beta-Testing. JMIR Mhealth Uhealth 5:e102

Showing the most recent 10 out of 76 publications